Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2704166 | 1.00 | PAX8 (0.32) | PAX8 | |
| SCHEMBL19295 | 1.00 | PAX8 (0.32) | PAX8 | |
| Hydrochloric Acid SCHEMBL5913921 | 0.98 | PAX8 (0.31) | PAX8 | |
| Sulfuric Acid SCHEMBL9863900 | 0.98 | PAX8 (0.31) | PAX8 | |
| Hydrazine SCHEMBL1326324 | 0.98 | PAX8 (0.31) | PAX8 | |
| Hydrochloric Acid SCHEMBL1814659 | 0.97 | PAX8 (0.30) | PAX8 | |
| Hydrochloric Acid SCHEMBL6929597 | 0.97 | PAX8 (0.30) | PAX8 | |
| Hydrochloric Acid SCHEMBL1199579 | 0.97 | PAX8 (0.30) | PAX8 | |
| SCHEMBL3748924 | 0.94 | USP2 (0.36) | PAX8 | |
| SCHEMBL6475497 | 0.94 | USP2 (0.36) | PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016174131-A1 | 4-EPI-ISOFAGOMINE ENANTIOMER DERIVATIVES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | DORPHAN S.A. (CH) | 2016-11-03 | — | — | WO | claimed |
| WO-2010022461-A1 | SULPHATED SUGARS TO INCREASE ACTIVITY OF SULPHATASES EN LYSOSOMAL STORAGE DISORDERS | CHILDREN, YOUTH AND WOMEN'S HEALTH SERVICE (AU) | 2010-03-04 | — | — | WO | claimed |
| US-20060188465-A1 | Cross-linked polymer of carbohydrate, notably based on polysaccharides, and/or on oligosaccharides and/or on polyols | ENGELHARD LYON (FR) | 2006-08-24 | — | — | US | claimed |
| US-20030162732-A1 | Combination of aminosugars and cysteine or cysteine derivatives | ASTION DEVELOPMENT A/S (DK) | 2003-08-28 | — | — | US | claimed |
| US-20030105034-A1 | Pyridine carboxy derivatives and an aminosugar | ASTION DEVEOPMENT A/S (DK) | 2003-06-05 | — | — | US | claimed |
| WO-2003002117-A2 | NIACIAMIDE AND DERIVATIVES IN COMBINATION WITH AMINOSUGAR | ASTION DEVELOPMENT A/S (DK) | 2003-01-09 | — | — | WO | claimed |
| WO-2003002125-A2 | COMBINATION OF AMINOSUGARS AND CYSTEINE OR CYSTEINE DERIVATIVES | ASTION A/S (DK) | 2003-01-09 | — | — | WO | claimed |
| US-6197757-B1 | ADMINISTERING ENCAPSULATED, CROSSLINKED DRUG, COSMETIC OR FOOD | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2001-03-06 | — | — | US | claimed |
| EP-4074331-B1 | COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES | REGENERON PHARMA (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20240293555-A1 | CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | CEDARS-SINAI MEDICAL CENTER | 2024-09-05 | — | — | US | disclosed |
| US-20240181079-A1 | PRODUCTION OF CIRCULAR POLYRIBONUCLEOTIDES IN A EUKARYOTIC SYSTEM | FLAGSHIP PIONEERING INNOVATIONS VII LLC (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240123083-A1 | HYBRID AAV-ANELLOVECTORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240000914-A1 | CHICKEN ANEMIA VIRUS (CAV)-BASED VECTORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230348933-A1 | TANDEM ANELLOVIRUS CONSTRUCTS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-11-02 | — | — | US | disclosed |
| EP-0606376-B1 | METHOD FOR GENETICALLY MODIFYING BONE MARROW CELLS OF PRIMATES, AND USEFUL CELLS THEREFOR THAT PRODUCE RECOMBINANT RETROVIRAL VECTORS | INTROGENE BV (NL) | 1998-05-13 | — | — | EP | disclosed |
| EP-0787201-A1 | POLY(ORGANO)PHOSPHAZENES FOR USE IN SYNTHETIC TRANSFECTION SYSTEMS | Introgene B.V. (NL) | 1997-08-06 | — | — | EP | disclosed |
| US-5612206-A | Retrovirus infecting primate bone marrow cells and harvesting both non-adherent and adherent cells | INTROGENE B.V. (NL) | 1997-03-18 | — | — | US | disclosed |
| WO-1997007226-A1 | POLY(ORGANO)PHOSPHAZENES FOR USE IN SYNTHETIC TRANSFECTION SYSTEMS | INTROGENE B.V. (NL) | 1997-02-27 | — | — | WO | disclosed |
| EP-0606376-A1 | METHOD FOR GENETICALLY MODIFYING BONE MARROW CELLS OF PRIMATES, AND USEFUL CELLS THEREFOR THAT PRODUCE RECOMBINANT RETROVIRAL VECTORS | Introgene B.V. (NL) | 1994-07-20 | — | — | EP | disclosed |
| WO-1993007281-A1 | METHOD FOR GENETICALLY MODIFYING BONE MARROW CELLS OF PRIMATES, AND USEFUL CELLS THEREFOR THAT PRODUCE RECOMBINANT RETROVIRAL VECTORS | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162732-A1 | Combination of aminosugars and cysteine or cysteine derivatives | CBS, CTH, AADAT | PAX8 2026/4885 |
| US-20030105034-A1 | Pyridine carboxy derivatives and an aminosugar | AADAT, CMA1, AASDHPPT | PAX8 739/4885 |
| US-20240293555-A1 | CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | CSGALNACT1, SLC2A8, FUT6 | PAX8 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.